Management challenge with drotrecogin alfa (activated).

Area of Science:

• Critical Care Medicine
• Pharmacoeconomics
• Health Services Research

Background:

• Sepsis treatment is resource-intensive, with intensive care unit (ICU) costs dominating overall expenses.
• Interdisciplinary collaboration and teamwork are vital for improving outcomes and reducing costs in critical care settings.
• Drotrecogin alfa (activated) represents a potential new therapeutic option for severe sepsis management.

Purpose of the Study:

• To evaluate the impact of drotrecogin alfa (activated) on morbidity and total healthcare costs in patients with severe sepsis.
• To assess the cost-effectiveness of drotrecogin alfa (activated) based on clinical trial data.
• To inform clinical decision-making regarding the integration of drotrecogin alfa (activated) into sepsis treatment protocols.

Main Methods:

• Analysis of clinical trial data for drotrecogin alfa (activated) in severe sepsis patients.
• Evaluation of morbidity and mortality rates at 28 days post-treatment.
• Assessment of total resource utilization and healthcare costs over a 28-day period.
• Calculation of cost per life-year saved for the intervention.

Main Results:

• Drotrecogin alfa (activated) significantly reduced mortality in severe sepsis patients within 28 days.
• No significant increase in major morbidity was observed in the drotrecogin alfa (activated) group.
• Total resource use did not differ significantly between the drotrecogin alfa (activated) and placebo groups over 28 days, despite higher survival rates in the treatment arm.
• Estimated costs per life-year saved were found to be within a cost-effective range.

Conclusions:

• Drotrecogin alfa (activated) offers a survival benefit in severe sepsis without a substantial increase in short-term morbidity.
• The pharmacoeconomic analysis suggests that drotrecogin alfa (activated) is a cost-effective treatment option for severe sepsis.
• Pharmacists should systematically evaluate the health value of drotrecogin alfa (activated) upon its clinical availability.